Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.

Gilead's adefovir dipivoxil patients should be monitored every four to eight weeks following initial dosing, FDA's Antiviral Drug Products Advisory Committee recommended during its Aug. 6 meeting